SCHEMBL16770352

SCHEMBL16770352

Clc1cc(-c2ccco2)nc2cc(-c3ccccc3)nn12

nearest known ligand 0.67

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 15/20 0.67
ABCG2 Q9UNQ0 5/20 0.56
ADORA2A P29274 1/20 0.53
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
RAB9A P51151 1/20 0.48
ALOX15 P16050 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16800298 0.84 ABCB1 (0.71) ABCB1ABCG2ADORA2AMEN1ALDH1A1
SCHEMBL13815718 0.82 DPP4 (0.49) ABCB1ABCG2ADORA2AMEN1ALDH1A1
SCHEMBL5455512 0.77 PDE10A (0.54) ABCB1ADORA2AMEN1ALDH1A1KMT2A
SCHEMBL13263646 0.76 NPC1 (0.53) MEN1ALDH1A1KMT2AKDM4EMAPT
SCHEMBL16386072 0.76 ALDH1A1 (0.50) ADORA2AMEN1ALDH1A1KMT2AKDM4E
SCHEMBL7063800 0.74 RAB9A (0.71) MEN1ALDH1A1KMT2AKDM4EMAPT
SCHEMBL3299677 0.73 TP53 (0.53) MEN1ALDH1A1KMT2AKDM4EMAPT
SCHEMBL23413228 0.71 PTGS1 (0.51) ABCB1ADORA2A
SCHEMBL23998420 0.71 ABCB1 (0.49) ABCB1ABCG2ADORA2AMEN1ALDH1A1
SCHEMBL8549227 0.71 MYC (0.70) ABCB1ADORA2AMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244457-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT UNIV KANSAS (US) 2016-08-25 US disclosed
US-20160244457-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT UNIV KANSAS (US) 2016-08-25 US disclosed
US-20160244457-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT UNIV KANSAS (US) 2016-08-25 US disclosed
US-20150197526-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT UNIVERSITY OF KANSAS 2015-07-16 US disclosed
US-20150197526-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT UNIVERSITY OF KANSAS 2015-07-16 US disclosed
US-20150197526-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT UNIVERSITY OF KANSAS 2015-07-16 US disclosed
US-9056111-B1 Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment STC.UNM (US) 2015-06-16 US disclosed
US-9056111-B1 Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment STC.UNM (US) 2015-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197526-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT ABCB1, ABCG2, ABCC5 ABCB1 1/4885ABCG2 2/4885ADORA2A 153/4885
US-20160244457-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT ABCB1, ABCG2, ABCC5 ABCB1 1/4885ABCG2 2/4885ADORA2A 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.